Drug Approval | June 06, 2022
FDA publishes ANP’s polymeric drug excipient DMF
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
Company will expand the existing production site in Wuxi to significantly increase biopharma single-use assemblies and custom design capabilities
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Study to evaluate effectiveness of hypoglossal nerve stimulation
Subscribe To Our Newsletter & Stay Updated
